📑 Table of Contents▼

Iproniazid
Clinical data
Trade namesMarsilid, others
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
Bioavailability1
Identifiers
  • N-isopropylisonicotinohydrazide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.199 Edit this at Wikidata
Chemical and physical data
FormulaC9H13N3O
Molar mass179.223 g·mol−1
3D model (JSmol)
Density1.084 g/cm3
Boiling point265.9 °C (510.6 °F)
  • O=C(NNC(C)C)c1ccncc1
  • InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13) checkY
  • Key:NYMGNSNKLVNMIA-UHFFFAOYSA-N checkY
  (verify)

Iproniazid (Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class.[1][2] It is a xenobiotic that was originally designed to treat tuberculosis, but was later most prominently used as an antidepressant drug. However, it was withdrawn from the market because of its hepatotoxicity.[3][4] The medical use of iproniazid was discontinued in most of the world in the 1960s, but remained in use in France until 2015.[5]

History

edit

Iproniazid was originally developed for the treatment of tuberculosis,[1] but in 1952, the compounds's antidepressant properties were discovered when researchers noted that patients became inappropriately happy when given isoniazid, a related antibiotic.[1][6] Subsequently, adding an isopropyl chain onto isoniazid led to the development of iproniazid as an antidepressant and it was approved for use in 1958.[1] It was withdrawn in most of the world a few years later in 1961 due to a high incidence of hepatitis, and was replaced by less hepatotoxic drugs such as phenelzine and isocarboxazid.[1] Canada withdrew iproniazid in July 1964 due to interactions with food products containing tyramine.[7][8] Despite its being swiftly withdrawn, iproniazid helped establish the relationship between psychiatric disorders and the metabolism of neurotransmitters.[4]

Although iproniazid was one of the first antidepressants ever marketed, dextroamphetamine (marketed as Benzedrine from 1935, for "mild depression", amid other indications)[9] predates it; and herbs like cannabis and frankincense have been used traditionally for millennia for, among other things, altering mood. It was not until 2012 that one of the components of frankincense smoke was found to have antidepressant effects in mice.[10] [11][12]

Structure and reactivity

edit

The structure of iproniazid is chemically, in both structure and reactivity, similar to isoniazid. Iproniazid is a substituted hydrazine of which the isopropyl hydrazine moiety is essential for the inhibition of monoamine oxidase activity.[13]

Synthesis

edit
This figure shows the multiple synthesis pathways towards iproniazid.

There are multiple routes to synthesize iproniazid. The most common precursor is methyl isonicotinate which formes isonicotinohydrazide when it reacts with hydrazine.[14] Isonicotinohydrazide can be converted into iproniazid via different pathways.

One synthesis pathway involves AcMe which results in the formation of N'-(propan-2-ylidene)isonicotinohydrazide. Subsequently, the C=N linkage is selectively hydrogenated in the presence of a platinum catalyst and with water, alcohol or acetic acid as solvent.[15][16]

In another pathway isonicotinohydrazide reacts with either 2-bromopropane or 2-chloropropane in an N-isopropyl addition reaction to the hydrazine moiety. This directly results in the formation of iproniazid.[17]

Reactions and mechanism of action

edit

Iproniazid inhibits the activity of monoamine oxidases (MAOs) both directly and by formation of an active metabolite, isopropylhydrazine. The formation of isopropylhydrazine from iproniazid has been observed without MAOs present.[13] Both iproniazid and isopropylhydrazine react near the active site of MAOs. The reaction is a progressive first-order reaction with a high activation energy. In the presence of oxygen it is an irreversible reaction, as dehydrogenation of iproniazid at the active site of the enzyme takes place. This dehydrogenation resembles the first step of amine oxidation. After dehydrogenation iproniazid further reacts with the enzyme.[18]

Inhibition of MAOs by iproniazid is competitive and sensitive to changes in pH and temperature, similar to oxidation of the monoamine substrate. Inhibition cannot be reversed by addition of the substrate.[18] Iproniazid is able to displace non-hydrazine inhibitors, but not other hydrazine inhibitors from the active site of the enzyme.[13]

To increase the inhibition of monoamine oxidase, cyanide can be used. The reaction however remains oxygen-dependent.[18] MAO inhibition can be decreased by addition of glutathione, suggesting non enzymatic conjugation of either iproniazid or isopropylhydrazine with glutathione.[18]

Metabolism and toxicity

edit
This figure shows the metabolism of iproniazid. The most important (proposed) metabolite is the isopropyl radical which is thought to be responsible for the heptatoxicity of iproniazid.[3][19]

Iproniazid is metabolized in the body. Iproniazid is converted to isopropyl hydrazine and isonicotinic acid in an initial hydrolysis reaction. Isopropyl hydrazine can either be released in the blood or it can be metabolically activated by microsomal CYP450 enzymes.[19] This oxidation of isopropyl hydrazine is a toxification reaction that eventually can lead to the formation of an alkylating agent: the isopropyl radical.[3] Hepatic necrosis was found in rats with doses as low as 10 mg/kg.[19]

Isopropyl radical

edit

The presence of the isopropyl radical was indicated by another observed product of the metabolism of iproniazid: the gas propane.[3]

Alkylating agents have the capability to bind to chemical groups such as amino, phosphate hydroxyl, imidazole and sulfhydryl groups. The formed isopropyl radical is able to form S-isopropyl conjugates in vitro. This diminishes covalent binding to other proteins, however it was only observed in vitro. In vivo, hepatotoxic doses of isopropyl hydrazine, the precursor of the isopropyl radical, did not deplete sulfhydryl-group containing compounds.[3]

Liver necrosis

edit

The isopropyl radical formed as a result of the metabolism of iproniazid, is able to covalently bind to proteins and other macromolecules in the liver. These interactions are the reason for the hepatotoxicity of iproniazid. Covalent binding results in liver necrosis by presumably changing protein function leading to organelle stress and acute toxicity.[20][21] However, the exact mechanism of how the binding of iproniazid derivatives to liver proteins would induce liver necrosis remains unclear.[3]

Cytochrome P450 enzymes are present at the highest concentrations in the liver, causing most alkylating agents to be produced in the liver. This explains why the liver is mostly damaged by covalent binding of alkylating agents such as the isopropyl radical.[19] Rat models and other animal models have shown that cytochrome P450 enzymes convert isopropyl hydrazine to alkylating compounds that induce liver necrosis. An inducer of a class of hepatic microsomal cytochrome P450 enzymes, phenobarbital, highly increased the chance of necrosis. In contrast, the compounds cobalt chloride, piperonyl butoxide and alpha-naphthylisothiocyanate inhibit microsomal enzymes which resulted in a decreased chance of necrosis due to isopropyl hydrazine.[19]

Metabolism to other forms

edit

Iproniazid can also be metabolised by O-dealkylation from iproniazid to acetone and isoniazid. Isoniazid can undergo further metabolism via multiple metabolic pathways, of which one eventually results in alkylating agents as well. This toxifying metabolic pathway includes N-acetylation. Reactions involving acetylation are influenced by genetic variance: the acetylator phenotype. The toxicological response to isoniazid (and thus iproniazid) can therefore be subjected to interindividual differences.

Acetone can also be produced in alternative pathway as a metabolite of isopropyl hydrazine. It is eventually converted to CO2 and exhaled.[3]

Isonicotinic acid

edit

Isonicotinic acid, formed during the hydrolysis of iproniazid, is described as a moderately toxic compound and allergen with cumulative effects.[22] Isonicotinic acid is further metabolized by glycine-conjugation or glucuronic acid-conjugation.[19][23]

Other toxic effects

edit

Iproniazid can also interact with tyrosine-containing food products which may have toxic effects.[7][8]

Excretion

edit

Excretion can occur via different routes: via the lungs, the urine, bile and sometimes via the skin or breast milk. Iproniazid has a molecular weight of 179.219 g/mol, which is far below 500 g/mol, and it is hydrophilic (because of e.g. the N-H groups in the molecule). These two properties together indicate that iproniazid is likely to be excreted in the urine via the kidneys.[24]

Iproniazid can also be metabolized and excreted afterwards in the form of one of its metabolites which can be found in the figure above. Isoniazid is hydrophilic[24] and has a molecular weight of 137.139 g/mol. Isoniazid is therefore expected to be excreted via the urine, if it is not further metabolized in the body. The same holds for isonicotinic acid and isonicotinoyl glycine. Carbon dioxide and propane are gaseous which are presumably transported out of the body by exhalation via the lungs.

Indication

edit

Iproniazid was originally produced as anti-tuberculosis medicine, but was also found to be effective as antidepressant. When it was discovered that iproniazid was hepatotoxic, it was replaced by medicinal xenobiotics that are less harmful to the liver. oderniantidepressants include socarboxazid, phenelzine, and tranylcypromine.[3]

Drugs more effective for treatment of tuberculosis are isoniazid, pyrazinamide, ethambutol and rifampicin.[25]

Efficacy and side effects

edit

Efficacy

edit

Iproniazid was designed to treat tuberculosis, but its most significant positive effect is that it has a mood-stimulating property. Therefore, it was used as an antidepressant drug.[8]

Adverse effects

edit

The most significant adverse effects of using iproniazid is the hepatotoxicity caused by its metabolites. Moreover, usage of iproniazid results in other adverse effects such as dizziness (when lying down), drowsiness, headaches, ataxia, numbness of the feet and hands, and muscular twitching. However, these adverse effects disappear after approximately 10 weeks.[26][27]

Effects on animals

edit

Rat animal models have been used to investigate the hepatotoxic (bio)chemical mechanism of iproniazid. A metabolite of iproniazid, isopropyl hydrazine, was found to be a potent hepatotoxin in rats.[3][19] Hepatic necrosis was found in rats with doses as low as 10 mg/kg.[19] It was predicted with admetSAR[28] that iproniazid had a LD50 of 2.6600 mol/kg in rats.[8]

Lethality

edit

See the table for experimentally determined LD50, TDLo and LDLo values of various organisms.

Organism Test Type Route Reported Dose (mg/kg) Reference
Dog LD50 oral 95 [29]
Human TDLo oral 2.143 /D Acta Neurologia et Psychiatrica Belgica. Vol. 59, Pg. 977, 1959.
Human LDLo oral 14 /2W-I [30]
Monkey LD50 oral 640 [29]
Mouse LD50 Intramuscular 615 [31]
Mouse LD50 intraperitoneal 475 [32]
Mouse LD50 intravenous 719 [31]
Mouse LD50 oral 440 [33]
Mouse LD50 subcateneous 730 [31]
Rabbit LD50 intravenous 117 [31]
Rabbit LD50 oral 125 [31]
Rabbit LDLo skin 2000 Huntingdon Research Center Reports. Vol. -, Pg. -, 1972.
Rat LD50 subcutaneous 538 [32]
Rat LD50 unreported 350 [34]
Rat LD50 oral 365 [35]
Rat LD50 intraperitoneal 375 [36]

See also

edit

References

edit
  1. ^ a b c d e Maxwell RA, Eckhardt SB (1990). "Iproniazid". Drug Discovery. Humana Press. pp. 143–154. ISBN 978-0-89603-180-7.
  2. ^ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical Pharmacology. 35 (8): 1381–1387. doi:10.1016/0006-2952(86)90285-6. PMID 2870717.
  3. ^ a b c d e f g h i Timbrell J (2008). Taylor & Francis Group. pp. 324–326. doi:10.3109/9781420007084. ISBN 978-0-8493-7302-2.
  4. ^ a b Henn F, Sartorius N, Helmchen H, Lauter H, eds. (2013-11-11). Contemporary Psychiatry. Springer Science & Business Media. p. 109. ISBN 978-3-642-59519-6.
  5. ^ Dormegny-Jeanjean LC, de Billy C, Mainberger O, Weibel S, Schorr B, Obrecht A, et al. (2023). "Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial - CADOT". Frontiers in Psychiatry. 14 1194090. doi:10.3389/fpsyt.2023.1194090. PMC 10565009. PMID 37829759.
  6. ^ Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK (April 2011). "Antidepressants: From MAOIs to SSRIs and more". Indian Journal of Psychiatry. 53 (2): 180–182. doi:10.4103/0019-5545.82567. PMC 3136031. PMID 21772661.
  7. ^ a b Alex A, Harris CJ, Smith DA (2015-10-26). Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward. John Wiley & Sons. ISBN 978-1-118-81944-9.
  8. ^ a b c d "Iproniazid". www.drugbank.ca. Retrieved 2018-03-27.
  9. ^ Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present--a pharmacological and clinical perspective". Journal of Psychopharmacology. 27 (6): 479–496. doi:10.1177/0269881113482532. PMC 3666194. PMID 23539642.
  10. ^ Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, et al. (August 2008). "Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain". FASEB Journal. 22 (8): 3024–3034. doi:10.1096/fj.07-101865. PMC 2493463. PMID 18492727.
  11. ^ Moussaieff A, Gross M, Nesher E, Tikhonov T, Yadid G, Pinhasov A (December 2012). "Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals". Journal of Psychopharmacology. 26 (12): 1584–1593. doi:10.1177/0269881112458729. PMID 23015543. S2CID 1675621.
  12. ^ Drahl C (22 December 2008). "Frankincense And Myrrh". Chemical & Engineering News. 86 (51): 38. doi:10.1021/cen-v086n051.p038. ISSN 0009-2347.
  13. ^ a b c Smith TE, Weissbach H, Udenfriend S (1963). "Studies on Monoamine Oxidase: The Mechanism of Inhibition of Monoamine Oxidase by Iproniazid". Biochemistry. 2 (4): 746–751. doi:10.1021/bi00904a021. PMID 14075108.
  14. ^ Pozsgay V, Jennings HJ (1987). "Azide synthesis with stable nitrosyl salts". Tetrahedron Letters. 28 (43): 5091–5092. doi:10.1016/s0040-4039(00)95598-9.
  15. ^ Yale HL, Losee K, Martins J, Holsing M, Perry FM, Bernstein J (1953). "Chemotherapy of Experimental Tuberculosis. VIII. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds1,2". Journal of the American Chemical Society. 75 (8): 1933–1942. Bibcode:1953JAChS..75.1933Y. doi:10.1021/ja01104a046.
  16. ^ Vigorita MG, Ottanà R, Maccari R, Monforte F, Bisignano G, Pizzimenti FC (1998). "Synthesis and in vitro antimicrobial and antitumoral screening of novel lipophilic isoniazid analogues. VI". Bollettino Chimico Farmaceutico. 137 (7): 267–276. PMID 9795482.
  17. ^ McMillan FH, Leonard F, Meltzer RI, King JA (August 1953). "Antitubercular substances. II. Substitution products of isonicotinic hydrazide". Journal of the American Pharmaceutical Association. American Pharmaceutical Association. 42 (8): 457–464. doi:10.1002/jps.3030420803. PMID 13069348.
  18. ^ a b c d Davison AN (October 1957). "The mechanism of the irreversible inhibition of rat-liver monoamine oxidase by iproniazid (marsilid)". The Biochemical Journal. 67 (2): 316–322. doi:10.1042/bj0670316. PMC 1200154. PMID 13471553.
  19. ^ a b c d e f g h Nelson SD, Mitchell JR, Snodgrass WR, Timbrell JA (September 1978). "Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine". The Journal of Pharmacology and Experimental Therapeutics. 206 (3): 574–585. doi:10.1016/S0022-3565(25)31362-5. PMID 702322.
  20. ^ Iorga A, Dara L, Kaplowitz N (May 2017). "Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis". International Journal of Molecular Sciences. 18 (5) 1018. doi:10.3390/ijms18051018. PMC 5454931. PMID 28486401.
  21. ^ Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB (October 1973). "Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism". The Journal of Pharmacology and Experimental Therapeutics. 187 (1): 185–194. doi:10.1016/S0022-3565(25)29663-X. PMID 4746326.
  22. ^ Tsarichenko GV, Bobrov VI, Smarkov MV (1977-04-01). "Toxicity of isonicotinic acid". Pharmaceutical Chemistry Journal. 11 (4): 481–483. doi:10.1007/BF01156485. ISSN 0091-150X. S2CID 9309017.
  23. ^ Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, et al. (January 2012). "A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct". Antimicrobial Agents and Chemotherapy. 56 (1): 28–35. doi:10.1128/AAC.05486-11. PMC 3256082. PMID 22037847.
  24. ^ a b de Sagher RM, De Leenheer AP, Claeys AE (June 1976). "Identification and quantitative GLC determination of iproniazid in human urine". Journal of Pharmaceutical Sciences. 65 (6): 878–882. Bibcode:1976JPhmS..65..878D. doi:10.1002/jps.2600650619. PMID 932974.
  25. ^ Te Brake LH, de Knegt GJ, de Steenwinkel JE, van Dam TJ, Burger DM, Russel FG, et al. (January 2018). "The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box". Annual Review of Pharmacology and Toxicology. 58 (1): 271–291. doi:10.1146/annurev-pharmtox-010617-052438. PMID 28715978.
  26. ^ Lichtenstein MR, Mizenberg E (May 1954). "A controlled study of isoniazid and iproniazid". Diseases of the Chest. 25 (5): 573–579. doi:10.1378/chest.25.5.573. PMID 13151011.
  27. ^ "Side Effects of Iproniazid". edudrugs.com. Retrieved 2018-03-27.
  28. ^ Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. (November 2012). "admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties". Journal of Chemical Information and Modeling. 52 (11): 3099–3105. doi:10.1021/ci300367a. PMID 23092397. S2CID 16356154.
  29. ^ a b Randall LO, Bagdon RE (September 1959). "Pharmacology of iproniazid and other amine oxidase inhibitors". Annals of the New York Academy of Sciences. 80 (3): 626–642. doi:10.1111/j.1749-6632.1959.tb49241.x. PMID 14436140.
  30. ^ deVerteuil RL, Lehmann HE (January 1958). "Therapeutic trial of iproniazid (marsilid) in depressed and apathetic patients". Canadian Medical Association Journal. 78 (2): 131–133. PMC 1829550. PMID 13489643.
  31. ^ a b c d e Benson WM, Stefko PL, Roe MD (April 1952). "Pharmacologic and toxicologic observations on hydrazine derivatives of isonicotinic acid (rimifon, marsilid)". American Review of Tuberculosis. 65 (4): 376–391. doi:10.1164/art.1952.65.4.376 (inactive 2 May 2026). PMID 14903505.{{cite journal}}: CS1 maint: DOI inactive as of May 2026 (link)
  32. ^ a b Nakamura K, Masuda Y, Tatsumi H, Fujimoto K (August 1963). "Structure and Activity Relationship of Monoamine Oxidase Inhibitors, Phenylacetylhydrazide Derivatives". Japanese Journal of Pharmacology. 13 (2): 186–194. doi:10.1254/jjp.13.186. PMID 14062711.
  33. ^ Myakushkene G, Rochka VS, Vainilavichus P (December 1996). "Synthesis and antimonoamineoxidase activity of 1-(2-pyrimidylcarbonyl)-2-arylmethyl and (1-arylethyl)hydrazines". Pharmaceutical Chemistry Journal. 30 (12): 750–752. doi:10.1007/BF02218827.
  34. ^ Logemann W, Lauria F, Artini D (February 1960). "Methanesulphonic acid derivatives of central stimulant drugs". Nature. 185 (4712): 532–533. doi:10.1038/185532a0. PMID 18985987.
  35. ^ Chessin M, Kramer ER, Scott CC (April 1957). "Modifications of the pharmacology of reserpine and serotonin by iproniazid". The Journal of Pharmacology and Experimental Therapeutics. 119 (4): 453–460. doi:10.1016/S0022-3565(25)11898-3. PMID 13429452.
  36. ^ Eidus L, Hodgkin MM (July 1975). "A new isoniazid preparation designed for moderately fast and "fast" metabolizers of the drug". Arzneimittel-Forschung. 25 (7): 1077–1080. PMID 1101901.

📚 Artikel Terkait di Wikipedia

ATC code N06

N06AF02 Nialamide N06AF03 Phenelzine N06AF04 Tranylcypromine N06AF05 Iproniazide N06AF06 Iproclozide N06AG02 Moclobemide N06AG03 Toloxatone N06AX01 Oxitriptan